PMID- 33946070
OWN - NLM
STAT- MEDLINE
DCOM- 20210818
LR  - 20210818
IS  - 1423-0232 (Electronic)
IS  - 0030-2414 (Linking)
VI  - 99
IP  - 8
DP  - 2021
TI  - Efficacy and Safety of Lenvatinib-Transcatheter Arterial Chemoembolization 
      Sequential Therapy for Patients with Intermediate-Stage Hepatocellular Carcinoma.
PG  - 507-517
LID - 10.1159/000515865 [doi]
AB  - INTRODUCTION: We evaluated the efficacy and safety of lenvatinib-transcatheter 
      arterial chemoembolization (LEN-TACE) sequential therapy for patients (n = 88) 
      with intermediate-stage hepatocellular carcinoma (HCC). METHODS: Eighty-eight 
      patients who obtained tumor control by LEN treatment were analyzed; 30 received 
      LEN followed by TACE (LEN-TACE sequential therapy), and 58 received LEN 
      monotherapy. Propensity score matching was performed, and the outcomes of 19 
      patients in the LEN-TACE group and 19 patients in the LEN-alone group were 
      compared. Objective response rate (ORR), progression-free survival (PFS), overall 
      survival (OS), incidence of adverse events (AEs), and change in albumin-bilirubin 
      (ALBI) score were evaluated. RESULTS: After matching, baseline characteristics 
      were similar between the groups. The ORR was 63.2% with LEN-TACE group and 63.2% 
      with the LEN-alone group. Multivariate analysis showed that addition of TACE 
      during LEN treatment (hazard ratio [HR] 0.264, 95% confidence interval [CI] 
      0.087-0.802, p =  0.019) and Child-Pugh score 5 (HR 0.223, 95% CI 0.070-0.704, p 
      = 0.011) were the significant factors for PFS. Median PFS was 11.6 months with 
      LEN-TACE and 10.1 months with LEN-alone. The survival rate of the LEN-TACE group 
      was significantly higher than that of the LEN-alone group (median survival time; 
      not reached vs. 16.9 months, p = 0.007). The incidence of common LEN-associated 
      AEs was similar between groups. Although elevated aspartate 
      aminotransferase/alanine aminotransferase and fever were more frequent with 
      LEN-TACE group, these events were manageable. CONCLUSION: For patients with 
      intermediate-stage HCC, LEN-TACE sequential therapy may provide a deep response 
      and favorable prognosis.
CI  - (c) 2021 S. Karger AG, Basel.
FAU - Ando, Yuwa
AU  - Ando Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan, 
      yuwando@hiroshima-u.ac.jp.
FAU - Kawaoka, Tomokazu
AU  - Kawaoka T
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Amioka, Kei
AU  - Amioka K
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Naruto, Kensuke
AU  - Naruto K
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Ogawa, Yutaro
AU  - Ogawa Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Yoshikawa, Yuki
AU  - Yoshikawa Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Kikukawa, Chihiro
AU  - Kikukawa C
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Kosaka, Yumi
AU  - Kosaka Y
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Uchikawa, Shinsuke
AU  - Uchikawa S
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Morio, Kei
AU  - Morio K
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Fujino, Hatsue
AU  - Fujino H
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Nakahara, Takashi
AU  - Nakahara T
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Murakami, Eisuke
AU  - Murakami E
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Yamauchi, Masami
AU  - Yamauchi M
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Tsuge, Masataka
AU  - Tsuge M
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Hiramatsu, Akira
AU  - Hiramatsu A
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Fukuhara, Takayuki
AU  - Fukuhara T
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb 
      Survivors Hospital, Hiroshima, Japan.
FAU - Mori, Nami
AU  - Mori N
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb 
      Survivors Hospital, Hiroshima, Japan.
FAU - Takaki, Shintaro
AU  - Takaki S
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb 
      Survivors Hospital, Hiroshima, Japan.
FAU - Tsuji, Keiji
AU  - Tsuji K
AD  - Department of Gastroenterology, Hiroshima Red Cross Hospital & Atomic-Bomb 
      Survivors Hospital, Hiroshima, Japan.
FAU - Nonaka, Michihiro
AU  - Nonaka M
AD  - Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima, Japan.
FAU - Hyogo, Hideyuki
AU  - Hyogo H
AD  - Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima, Japan.
FAU - Aisaka, Yasuyuki
AU  - Aisaka Y
AD  - Department of Gastroenterology, JA Hiroshima General Hospital, Hiroshima, Japan.
FAU - Masaki, Keiichi
AU  - Masaki K
AD  - Department of Gastroenterology, Hiroshima City Asa Hospital, Hiroshima, Japan.
FAU - Honda, Yoji
AU  - Honda Y
AD  - Department of Gastroenterology, Hiroshima City Asa Hospital, Hiroshima, Japan.
FAU - Moriya, Takashi
AU  - Moriya T
AD  - Department of Gastroenterology, Chugoku Rosai Hospital, Hiroshima, Japan.
FAU - Naeshiro, Noriaki
AU  - Naeshiro N
AD  - Department of Gastroenterology, National Hospital Organization Higashihiroshima 
      Medical Center, Hiroshima, Japan.
FAU - Takahashi, Shoichi
AU  - Takahashi S
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Imamura, Michio
AU  - Imamura M
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
FAU - Chayama, Kazuaki
AU  - Chayama K
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
AD  - Research Center for Hepatology and Gastroenterology, Hiroshima University, 
      Hiroshima, Japan.
AD  - Institute of Physical and Chemical Research (RIKEN) Center for Integrative 
      Medical Sciences, Yokohama, Japan.
FAU - Aikata, Hiroshi
AU  - Aikata H
AD  - Department of Gastroenterology and Metabolism, Graduate School of Biomedical and 
      Health Sciences, Hiroshima University, Hiroshima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20210504
PL  - Switzerland
TA  - Oncology
JT  - Oncology
JID - 0135054
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Quinolines)
RN  - EE083865G2 (lenvatinib)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/administration & dosage/adverse effects
MH  - Carcinoma, Hepatocellular/pathology/*therapy
MH  - Chemoembolization, Therapeutic/adverse effects/*methods
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Liver Neoplasms/pathology/*therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phenylurea Compounds/*administration & dosage/adverse effects
MH  - Progression-Free Survival
MH  - Propensity Score
MH  - Quinolines/*administration & dosage/adverse effects
MH  - Retrospective Studies
MH  - Survival Rate
OTO - NOTNLM
OT  - Hepatocellular carcinoma
OT  - Intermediate
OT  - Lenvatinib
OT  - Sequential therapy
OT  - Transcatheter arterial chemoembolization
EDAT- 2021/05/05 06:00
MHDA- 2021/08/19 06:00
CRDT- 2021/05/04 20:23
PHST- 2021/02/15 00:00 [received]
PHST- 2021/03/13 00:00 [accepted]
PHST- 2021/05/05 06:00 [pubmed]
PHST- 2021/08/19 06:00 [medline]
PHST- 2021/05/04 20:23 [entrez]
AID - 000515865 [pii]
AID - 10.1159/000515865 [doi]
PST - ppublish
SO  - Oncology. 2021;99(8):507-517. doi: 10.1159/000515865. Epub 2021 May 4.